Relationship between vasopressin and the renin-angiotensin-aldosterone system in essential hypertension: effect of converting enzyme inhibitor on plasma vasopressin. 1985

A Santucci, and R Leonetti Luparini, and C Ferri, and C Ficara, and C Giarrizzo, and F Balsano

The effect of the chronic administration of captopril on plasma levels of vasopressin (PVP) were studied in 14 patients with moderate essential hypertension and 10 normal volunteers. All patients were studied after 10 days without drugs and under a constant diet (120 mmol sodium and 80 mmol potassium/day). Plasma levels of renin activity (PRA), aldosterone (PA) and PVP were assayed before and after captopril treatment (50-100 mg/day for 1 month). In addition to the well-known effect of captopril treatment on PRA and PA, a statistically significant reduction of PVP was observed. This finding suggests that the renin-angiotensin-aldosterone system influences vasopressin release, and its inhibitors may contribute to the absence of water retention during captopril treatment compared with the effect of other vasodilatory drugs.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D012084 Renin-Angiotensin System A BLOOD PRESSURE regulating system of interacting components that include RENIN; ANGIOTENSINOGEN; ANGIOTENSIN CONVERTING ENZYME; ANGIOTENSIN I; ANGIOTENSIN II; and angiotensinase. Renin, an enzyme produced in the kidney, acts on angiotensinogen, an alpha-2 globulin produced by the liver, forming ANGIOTENSIN I. Angiotensin-converting enzyme, contained in the lung, acts on angiotensin I in the plasma converting it to ANGIOTENSIN II, an extremely powerful vasoconstrictor. Angiotensin II causes contraction of the arteriolar and renal VASCULAR SMOOTH MUSCLE, leading to retention of salt and water in the KIDNEY and increased arterial blood pressure. In addition, angiotensin II stimulates the release of ALDOSTERONE from the ADRENAL CORTEX, which in turn also increases salt and water retention in the kidney. Angiotensin-converting enzyme also breaks down BRADYKININ, a powerful vasodilator and component of the KALLIKREIN-KININ SYSTEM. Renin-Angiotensin-Aldosterone System,Renin Angiotensin Aldosterone System,Renin Angiotensin System,System, Renin-Angiotensin,System, Renin-Angiotensin-Aldosterone
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D002216 Captopril A potent and specific inhibitor of PEPTIDYL-DIPEPTIDASE A. It blocks the conversion of ANGIOTENSIN I to ANGIOTENSIN II, a vasoconstrictor and important regulator of arterial blood pressure. Captopril acts to suppress the RENIN-ANGIOTENSIN SYSTEM and inhibits pressure responses to exogenous angiotensin. (S)-1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline,Capoten,Lopirin,SQ-14,225,SQ-14,534,SQ-14225,SQ-14534,SQ 14,225,SQ 14,534,SQ 14225,SQ 14534,SQ14,225,SQ14,534,SQ14225,SQ14534
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

A Santucci, and R Leonetti Luparini, and C Ferri, and C Ficara, and C Giarrizzo, and F Balsano
February 1978, The Journal of clinical endocrinology and metabolism,
A Santucci, and R Leonetti Luparini, and C Ferri, and C Ficara, and C Giarrizzo, and F Balsano
January 1983, Nihon Jinzo Gakkai shi,
A Santucci, and R Leonetti Luparini, and C Ferri, and C Ficara, and C Giarrizzo, and F Balsano
June 1982, Zhonghua xin xue guan bing za zhi,
A Santucci, and R Leonetti Luparini, and C Ferri, and C Ficara, and C Giarrizzo, and F Balsano
January 1985, Nihon Jinzo Gakkai shi,
A Santucci, and R Leonetti Luparini, and C Ferri, and C Ficara, and C Giarrizzo, and F Balsano
September 1981, British journal of clinical pharmacology,
A Santucci, and R Leonetti Luparini, and C Ferri, and C Ficara, and C Giarrizzo, and F Balsano
December 1984, Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete,
A Santucci, and R Leonetti Luparini, and C Ferri, and C Ficara, and C Giarrizzo, and F Balsano
May 1975, Horumon to rinsho. Clinical endocrinology,
A Santucci, and R Leonetti Luparini, and C Ferri, and C Ficara, and C Giarrizzo, and F Balsano
November 1973, Nihon rinsho. Japanese journal of clinical medicine,
A Santucci, and R Leonetti Luparini, and C Ferri, and C Ficara, and C Giarrizzo, and F Balsano
January 1975, Kardiologia polska,
A Santucci, and R Leonetti Luparini, and C Ferri, and C Ficara, and C Giarrizzo, and F Balsano
April 2021, ESC heart failure,
Copied contents to your clipboard!